Detalles de la búsqueda
1.
Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.
Immunol Rev
; 270(1): 95-112, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26864107
2.
The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.
J Immunol
; 197(3): 807-13, 2016 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27316683
3.
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
Haematologica
; 101(5): 616-25, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-26858358
4.
Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.
Haematologica
; 100(2): 263-8, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25510242
5.
When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy.
Transfusion
; 55(6 Pt 2): 1555-62, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25988285
6.
Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition.
J Immunol
; 187(6): 3383-90, 2011 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21832160
7.
Systematic study of tissue factor expression in solid tumors.
Cancer Rep (Hoboken)
; 6(2): e1699, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36806722
8.
Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage.
J Immunol
; 184(1): 512-20, 2010 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19949082
9.
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.
Cancer Discov
; 12(5): 1233-1247, 2022 05 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35135829
10.
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors.
Nat Cancer
; 3(4): 418-436, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35469014
11.
Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII).
Cancer Sci
; 102(10): 1761-8, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21718386
12.
The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility.
Proc Natl Acad Sci U S A
; 105(16): 6109-14, 2008 Apr 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-18427122
13.
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells.
Blood
; 112(6): 2390-9, 2008 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18566325
14.
Retraction for Lammerts van Bueren et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility.
Proc Natl Acad Sci U S A
; 109(14): 5548, 2012 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-22431606
15.
Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action.
Cancer Res
; 66(15): 7630-8, 2006 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16885363
16.
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.
MAbs
; 7(2): 311-21, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25760767
17.
Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPß-dependent suppression of EGFR expression.
Neoplasia
; 14(3): 190-205, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22496619
18.
Novel human antibody therapeutics: the age of the Umabs.
Biotechnol J
; 3(9-10): 1157-71, 2008 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18702090
19.
Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations.
J Immunol
; 180(6): 4338-45, 2008 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18322248
20.
Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies.
Cancer Res
; 68(13): 4998-5003, 2008 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18593896